A more accurate screening test for prostate cancer?

HomeScience ReportsReports and NewsHealth and Medicine

A more accurate screening test for prostate cancer?

21.02.2005

New marker in urine may improve on PSA testing, reduce unnecessary biopsies

Men middle-aged and older routinely get blood tests for prostate-specific antigen, or PSA, to screen for prostate cancer. However, PSA testing has shortcomings: many men with elevated PSAs don’t have prostate cancer and undergo unnecessary biopsies, which can cause infertility, incontinence, and impotence. Other men do have prostate cancer, but have normal PSAs, allowing the cancer to spread undetected. A preliminary study from Children’s Hospital Boston, led by Dr. Bruce Zetter, shows that a simple urine test may improve upon PSA screening. Results appear in the Jan. 21 online edition of the journal Prostate.

Zetter, a researcher in the Vascular Biology Program at Children’s, is interested in the role of cell motility -- cells’ ability to move and travel -- in helping cancers to metastasize. He became especially interested in thymosin ß15, a protein that stimulates cell migration and promotes metastasis in prostate cancer. Unlike PSA, it is produced almost exclusively by cancer cells, and is detectable in urine.

In this study, Zetter and colleagues compared thymosin ß15 levels in urine samples from 121 men with prostate cancer, 15 men with other genitourinary cancers (kidney or bladder cancer), 81 men with non-malignant prostate disease (such as prostatitis), 73 men with other non-malignant urologic diseases (such as urinary tract infection), and 52 healthy men who served as controls. Thymosin ß15 levels were elevated in men with aggressive or untreated prostate cancer, but normal or near-normal in healthy men and men with other genitourinary diseases. Men with aggressive prostate cancer were 12 times more likely than the healthy controls to have elevated thymosin ß15.

Notably, nearly half of cancer patients whose PSA levels were considered normal tested positive for thymosin ß15. Conversely, many men with other genitourinary diseases had elevated PSAs, but normal thymosin ß15 values. When PSA and thymosin ß15 were combined, the combination detected prostate cancer more often than PSA testing alone, with far fewer false-positives.

Zetter, who is also Children’s Chief Scientific Officer, is now following the long-term outcomes of men with prostate cancer to determine thymosin ß15’s usefulness as a prognostic predictor in combination with PSA testing.

The Vascular Biology Program at Children’s is also actively studying urinary markers for other cancers. In a small pilot study, Dr. Marsha Moses and postdoctoral fellow Dr. Roopali Roy recently found that a compound called ADAM 12, when detected in urine, is an early marker of breast cancer. Another group of markers will soon enter formal clinical trials in adults with prostate, breast, bladder, lung, and colon cancer.

Bess Andrews | EurekAlert!
Further information:
http://www.childrenshospital.org/research

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

Im Focus: The Future of Ultrafast Solid-State Physics

In an article that appears in the journal “Review of Modern Physics”, researchers at the Laboratory for Attosecond Physics (LAP) assess the current state of the field of ultrafast physics and consider its implications for future technologies.

Physicists can now control light in both time and space with hitherto unimagined precision. This is particularly true for the ability to generate ultrashort...

All Focus news of the innovation-report >>>

Top

Send this article

Forum for Science, Industry and Business